Last reviewed · How we verify
Metformin plus Pioglitazone plus an SGLT2 inhibitor
Metformin plus Pioglitazone plus an SGLT2 inhibitor is a Small molecule drug developed by Chang Gung Memorial Hospital. It is currently in Phase 2 development.
At a glance
| Generic name | Metformin plus Pioglitazone plus an SGLT2 inhibitor |
|---|---|
| Sponsor | Chang Gung Memorial Hospital |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Oral Anti Diabetic Agents in the Hospital (PHASE4)
- Prevention of Progression of Prediabetes, Obesity and CV Risk (PHASE1)
- Pioglitazone and SGLT2 Inhibitors vs. DPP4 Inhibitors in Patients With Stroke (PHASE2)
- Quadruple Oral Combination Therapy for Type 2 Diabetes Mellitus : Glycemic Control by Thiazolidinedione (TZD) or Sodium Glucose Co-transporter 2 (SGLT-2) Inhibitor as an add-on Therapy in Type 2 Diabetes Mellitus After Failure of an Oral Triple Antidiabetic Regimen (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Metformin plus Pioglitazone plus an SGLT2 inhibitor CI brief — competitive landscape report
- Metformin plus Pioglitazone plus an SGLT2 inhibitor updates RSS · CI watch RSS
- Chang Gung Memorial Hospital portfolio CI
Frequently asked questions about Metformin plus Pioglitazone plus an SGLT2 inhibitor
What is Metformin plus Pioglitazone plus an SGLT2 inhibitor?
Metformin plus Pioglitazone plus an SGLT2 inhibitor is a Small molecule drug developed by Chang Gung Memorial Hospital.
Who makes Metformin plus Pioglitazone plus an SGLT2 inhibitor?
Metformin plus Pioglitazone plus an SGLT2 inhibitor is developed by Chang Gung Memorial Hospital (see full Chang Gung Memorial Hospital pipeline at /company/chang-gung-memorial-hospital).
What development phase is Metformin plus Pioglitazone plus an SGLT2 inhibitor in?
Metformin plus Pioglitazone plus an SGLT2 inhibitor is in Phase 2.